Literature DB >> 26096663

Red blood cell replacement, or nanobiotherapeutics with enhanced red blood cell functions?

Thomas Ming Swi Chang1.   

Abstract

Why is this important? Under normal circumstances, donor blood is the best replacement for blood. However, there are exceptions: During natural epidemics (e.g., HIV, Ebola, etc.) or man-made epidemics (terrorism, war, etc.), there is a risk of donor blood being contaminated, and donors being disqualified because they have contracted disease. Unlike red blood cells (RBCs), blood substitutes can be sterilized to remove infective agents. Heart attack and stroke are usually caused by obstruction of arterial blood vessels. Unlike RBCs, which are particulate, blood substitutes are in the form of a solution that can perfuse through obstructed vessels with greater ease to reach the heart and brain, as has been demonstrated in animal studies. Severe blood loss from injuries sustained during accidents, disasters, or war may require urgent blood transfusion that cannot wait for transportation to the hospital for blood group testing. Unlike RBCs, blood substitutes do not have specific blood groups, and can be administered on the spot. RBCs have to be stored under refrigeration for up to 42 days, and are thus difficult to transport and store in times of disaster and at the battlefront. Blood substitutes can be stored at room temperature for more than 1 year, compared to the RBC shelf life of 1 day, at room temperature. In cases of very severe hemorrhagic shock, there is usually a safety window of 60 min for blood replacement, beyond which there could be problems related to irreversible shock. Animal studies show that a particular type of blood substitute, with enhanced RBC enzymes, may be able to prolong the duration of the safety window.

Entities:  

Keywords:  antioxidant; blood substitiute; carbon dioxide transport; carbonic anhydrase; catalase; donor blood; hemoglobin; irreversible hemorrhagic shock; oxygen carrier; superoxide dismutase

Mesh:

Substances:

Year:  2015        PMID: 26096663     DOI: 10.3109/21691401.2015.1047557

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  2 in total

1.  Application of Perioperative Transfusion Trigger Score in Patients Undergoing Surgical Treatment of Malignant Tumor.

Authors:  Fan Zhang; Ze-Bing Zheng; Zhao-Qiong Zhu; De-Xing Liu; Jin Liu
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-12       Impact factor: 0.900

2.  Albumin-derived perfluorocarbon-based artificial oxygen carriers can avoid hypoxic tissue damage in massive hemodilution.

Authors:  Anna Wrobeln; Johannes Jägers; Theresa Quinting; Timm Schreiber; Michael Kirsch; Joachim Fandrey; Katja B Ferenz
Journal:  Sci Rep       Date:  2020-07-20       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.